AI-generated analysis. Always verify with the original filing.
IGC Pharma, Inc. entered into a Securities Purchase Agreement on March 5, 2026, issuing a $353,050 principal promissory note (with $46,050 OID) to Vanquish Funding Group Inc. for $307,000, maturing February 28, 2027, convertible upon default at 75% of the lowest trading price over prior 10 trading days. The Company also received approximately $219,000 under a loan agreement with One Deck Capital, Inc. for general working capital purposes.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into a Securities Purchase Agreement (the “Purch
. Item 3.02 Unregistered Sales of Equity Securities. The information set forth under Item 1.01 above is incorporated by reference into this Item 3.02. Any Conve
. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Securities Purchase Agreement, dated March 5, 2026, by and between IGC Pharma, I
Material Agreement
Debt / Financing